SG Americas Securities LLC Makes New $110,000 Investment in Acelyrin, Inc. (NASDAQ:SLRN)

SG Americas Securities LLC purchased a new stake in Acelyrin, Inc. (NASDAQ:SLRN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 14,741 shares of the company’s stock, valued at approximately $110,000.

Other hedge funds have also modified their holdings of the company. Osaic Holdings Inc. bought a new stake in Acelyrin in the second quarter valued at approximately $25,000. Amalgamated Bank bought a new stake in shares of Acelyrin in the 3rd quarter valued at $44,000. Tower Research Capital LLC TRC bought a new stake in shares of Acelyrin in the 2nd quarter valued at $64,000. Strs Ohio acquired a new stake in Acelyrin during the 3rd quarter worth $71,000. Finally, New York State Common Retirement Fund bought a new position in Acelyrin during the third quarter worth about $73,000. 87.31% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Shao-Lee Lin sold 15,701 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $7.60, for a total transaction of $119,327.60. Following the completion of the transaction, the chief executive officer now directly owns 1,587,335 shares in the company, valued at approximately $12,063,746. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Wall Street Analysts Forecast Growth

SLRN has been the subject of several recent analyst reports. Wells Fargo & Company increased their price target on Acelyrin from $11.00 to $13.00 and gave the stock an “equal weight” rating in a report on Thursday, March 21st. HC Wainwright reissued a “buy” rating and set a $28.00 target price on shares of Acelyrin in a research note on Monday, April 1st. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.67.

Acelyrin Stock Performance

NASDAQ SLRN opened at $5.01 on Friday. Acelyrin, Inc. has a 52 week low of $4.74 and a 52 week high of $29.88. The stock’s 50 day moving average price is $7.20 and its two-hundred day moving average price is $7.80. The stock has a market capitalization of $492.78 million and a price-to-earnings ratio of -0.47.

Acelyrin (NASDAQ:SLRN) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.25. On average, equities research analysts forecast that Acelyrin, Inc. will post -4.18 EPS for the current year.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.